trial

Genetics and Psychopathology in the 22q11 Deletion Syndrome

NCTId NCT00161109
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Unknown
Enrollment 175
Sponsored by UMC Utrecht
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Unknown
Enrollment
175
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2002-10
Primary completion
—
Eligibility
ALL · 8 Years · 20 Years

Interventions & indications

Drugs
—

Sponsors

UMC UtrechtLead Sponsor
Netherlands Brain FoundationCollaborator
Children's Hospital of PhiladelphiaCollaborator

Investigators

1
René S. Kahn, M.D., Ph.D.Study Director

Sites

2 total
Philadelphia, United StatesUtrecht, Netherlands

Facts & assertions

3 sourced
Enrollment
175
Phase
NA
Status
UNKNOWN
relationships
The graph out of here
lead_sponsor
UMC Utrecht
company
collaborator
Netherlands Brain Foundation
company
Children's Hospital of Philadelphia
company
indication
Chromosome 22q11.2 Deletion Syndrome
indication
DiGeorge Syndrome
indication
Autistic Disorder
indication
investigator
René S. Kahn, M.D., Ph.D.
person